公开(公告)号：WO2016205942A1

公开(公告)日：2016-12-29

申请号：PCT/CA2016/050734

申请日：2016-06-23

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： SAMPSON, Peter Brent ,  PATEL, Narendra Kumar B. ,  PAULS, Heinz W. ,  LI, Sze-Wan ,  NG, Grace ,  LAUFER, Radoslaw ,  LIU, Yong ,  LANG, Yunhui

IPC: C07D495/04 ,  A61K31/4436 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/551 ,  A61K39/395 ,  A61P35/00

CPC classification number: C07D495/04 ,  A61K31/4436 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/551 ,  A61K39/395 ,  A61K45/06 ,  A61K2039/505 ,  A61P35/00 ,  C07K16/2818 ,  A61K2300/00

Abstract: Thienopyridinone compounds of Formula (I) and pharmaceutically acceptable salts thereof are described. In these compounds, one of X 1 ; X 2 , and X 3 is S and the other two are each independently CR, wherein R and all other variables are as defined herein. The compounds are shown to inhibit HPK1 kinase activity and to have in vivo antitumor activity. The compounds can be effectively combined with pharmaceutically acceptable carriers and also with other immunomodulatory approaches, such as checkpoint inhibition or inhibitors of tryptophan oxidation. Formula (I).

Abstract translation: 描述了式（I）的噻吩并吡啶酮化合物及其药学上可接受的盐。 在这些化合物中，X1中的一种; X 2和X 3为S，另外两个各自独立地为CR，其中R和所有其它变量如本文所定义。 显示这些化合物抑制HPK1激酶活性并具有体内抗肿瘤活性。 化合物可以有效地与药学上可接受的载体组合，也可以与其他免疫调节方法如检查点抑制或色氨酸氧化抑制剂组合。 式（I）。

公开(公告)号：WO2014056083A1

公开(公告)日：2014-04-17

申请号：PCT/CA2013/000859

申请日：2013-10-11

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： LIU, Yong ,  LANG, Yunhui ,  NG, Grace ,  LI, Sze-Wan ,  PAULS, Heinz W. ,  LAUFER, Radoslaw ,  PATEL, Narendra Kumar B. ,  SAMPSON, Peter Brent ,  FEHER, Miklos ,  AWREY, Donald E.

IPC: C07D451/06 ,  A61K31/416 ,  A61K31/4439 ,  A61P35/00 ,  C07D401/12 ,  C07D405/12 ,  C07D405/14 ,  C07D498/08

CPC classification number: C07D498/08 ,  C07D231/56 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D409/14 ,  C07D451/06

Abstract: The invention is a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. Values for the variables are provided herein. Also included is a pharmaceutical composition comprising the compound represented by Structural Formula (I) and a pharmaceutically acceptable carrier or diluent and methods of treating a subject with cancer with the compound of Structural Formula (I).

Abstract translation: 本发明是由结构式（I）表示的化合物或其药学上可接受的盐。 这里提供了变量的值。 还包括药物组合物，其包含由结构式（I）表示的化合物和药学上可接受的载体或稀释剂以及用结构式（I）的化合物治疗患有癌症的受试者的方法。

公开(公告)号：WO2011123937A1

公开(公告)日：2011-10-13

申请号：PCT/CA2011/000366

申请日：2011-04-06

Applicant: UNIVERSITY HEALTH NETWORK ,  LAUFER, Radoslaw ,  PAULS, Heinz W. ,  FEHER, Miklos ,  NG, Grace ,  LIU, Yong ,  EDWARDS, Louise G. ,  PATEL, Narendra Kumar B. ,  PAN, Guohua ,  MAK, Tak W.

Inventor： LAUFER, Radoslaw ,  PAULS, Heinz W. ,  FEHER, Miklos ,  NG, Grace ,  LIU, Yong ,  EDWARDS, Louise G. ,  PATEL, Narendra Kumar B. ,  PAN, Guohua ,  MAK, Tak W.

IPC: C07D231/56 ,  A61K31/416 ,  A61P35/00 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12

CPC classification number: C07D231/56 ,  A61K31/00 ,  A61K31/517 ,  A61K31/522 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12

Abstract: The present teachings provide a compound represented by Strutural Formula (I): or a pharmaceutically acceptable salt thereof. Also described are a pharmaceutical composition and method of use thereof.

Abstract translation: 本发明提供由式（I）表示的化合物或其药学上可接受的盐。 还描述了药物组合物及其使用方法。

公开(公告)号：WO2015070349A1

公开(公告)日：2015-05-21

申请号：PCT/CA2014/051091

申请日：2014-11-14

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： LAUFER, Radoslaw ,  NG, Grace ,  LI, Sze-Wan ,  PAULS, Heinz W. ,  LIU, Yong ,  PATEL, Narendra Kumar B.

IPC: C07D487/04 ,  A61K31/519 ,  A61P35/00

CPC classification number: C07D487/04 ,  C07D519/00

Abstract: The present teachings provide a compound represented by the following structural formula: (Formula (I)); or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof.

Abstract translation: 本发明提供由以下结构式表示的化合物：（式（I））; 或其药学上可接受的盐。 还描述了药物组合物及其使用方法。

公开(公告)号：WO2014075168A1

公开(公告)日：2014-05-22

申请号：PCT/CA2013/000957

申请日：2013-11-15

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： LIU, Yong ,  PAULS, Heinz W. ,  LAUFER, Radoslaw ,  LI, Sze-Wan ,  SAMPSON, Peter Brent ,  FEHER, Miklos ,  NG, Grace ,  PATEL, Narendra Kumar B. ,  LANG, Yunhui

IPC: C07D487/04 ,  A61K31/519 ,  A61P35/00

CPC classification number: C07D487/04 ,  C07D519/00

Abstract: The present teachings provide a compound represented by structural formula (1-0), or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof.

Abstract translation: 本发明提供由结构式（1-0）表示的化合物或其药学上可接受的盐。 还描述了药物组合物及其使用方法。

公开(公告)号：WO2011123947A1

公开(公告)日：2011-10-13

申请号：PCT/CA2011/000387

申请日：2011-04-06

Applicant: UNIVERSITY HEALTH NETWORK ,  CUMMINGS, Graham ,  PATEL, Narenda Kumar B. ,  FORREST, Bryan, T. ,  LIU, Yong ,  LI, Sze-Wan ,  SAMPSON, Peter Brent ,  EDWARDS, Louise, G. ,  PAULS, Heinz W.

Inventor： CUMMINGS, Graham ,  PATEL, Narenda Kumar B. ,  FORREST, Bryan, T. ,  LIU, Yong ,  LI, Sze-Wan ,  SAMPSON, Peter Brent ,  EDWARDS, Louise, G. ,  PAULS, Heinz W.

IPC: C07D403/04 ,  C07D231/56 ,  C07D413/14

CPC classification number: C07D403/10 ,  A61K31/5377 ,  A61K45/06 ,  C07D231/56 ,  C07D403/04 ,  C07D403/14 ,  C07D413/14

Abstract: The present invention is directed to novel synthetic methods for preparing cyclopropyl indolinone compound represented by Structural Formula (A): (A) or its pharmaceutically acceptable salt thereof. Also included are synthetic intermediates described herein.

Abstract translation: 本发明涉及用于制备由结构式（A）表示的环丙基吲哚啉酮化合物的新型合成方法：（A）或其药学上可接受的盐。 还包括本文所述的合成中间体。

公开(公告)号：WO2011123946A1

公开(公告)日：2011-10-13

申请号：PCT/CA2011/000386

申请日：2011-04-06

Applicant: UNIVERSITY HEALTH NETWORK ,  SAMPSON, Peter Brent ,  LIU, Yong ,  LI, Sze-Wan ,  FORREST, Bryan T. ,  PAULS, Heinz W. ,  EDWARDS, Louise G. ,  FEHER, Miklos ,  PATEL, Narendra Kumar B. ,  LAUFER, Radoslaw ,  PAN, Guohua

Inventor： SAMPSON, Peter Brent ,  LIU, Yong ,  LI, Sze-Wan ,  FORREST, Bryan T. ,  PAULS, Heinz W. ,  EDWARDS, Louise G. ,  FEHER, Miklos ,  PATEL, Narendra Kumar B. ,  LAUFER, Radoslaw ,  PAN, Guohua

IPC: C07D413/14 ,  A61K31/5377 ,  A61P35/00 ,  C07D403/04

CPC classification number: C07D403/10 ,  A61K31/5377 ,  A61K45/06 ,  C07D231/56 ,  C07D403/04 ,  C07D403/14 ,  C07D413/14

Abstract: The invention is directed to a compound represented by the following structural formula pharmaceutically acceptable salts thereof: (I). Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.

Abstract translation: 本发明涉及由以下结构式表示的化合物其药学上可接受的盐：（I）。 由该结构式表示的化合物是激酶抑制剂，因此在此公开用于治疗癌症。 本文提供了结构式中变量的定义。

公开(公告)号：WO2010115279A1

公开(公告)日：2010-10-14

申请号：PCT/CA2010/000518

申请日：2010-04-06

Applicant: UNIVERSITY HEALTH NETWORK ,  SAMPSON, Peter Brent ,  Ll, Sze-Wan ,  LIU, Yong ,  PAULS, Heinz W. ,  EDWARDS, Louise G. ,  FORREST, Bryan T. ,  FEHER, Miklos ,  PATEL, Narendra Kumar B. ,  PAN, Guohua

Inventor： SAMPSON, Peter Brent ,  Ll, Sze-Wan ,  LIU, Yong ,  PAULS, Heinz W. ,  EDWARDS, Louise G. ,  FORREST, Bryan T. ,  FEHER, Miklos ,  PATEL, Narendra Kumar B. ,  PAN, Guohua

IPC: C07D403/04 ,  A61K31/416 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/496 ,  A61K31/5377 ,  A61P35/00 ,  C07D401/14 ,  C07D409/14 ,  C07D413/14

CPC classification number: A61K31/553 ,  A61K31/416 ,  A61K31/437 ,  A61K31/496 ,  A61K31/5377 ,  A61K45/06 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D409/14 ,  C07D413/14 ,  C07D471/04 ,  C07D471/10

Abstract: The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.

Abstract translation: 本发明涉及由以下结构式表示的化合物及其药学上可接受的盐：由该结构式表示的化合物是激酶抑制剂，因此本文公开了用于治疗癌症的化合物。 本文提供了结构式中变量的定义。

公开(公告)号：WO2013053051A1

公开(公告)日：2013-04-18

申请号：PCT/CA2012/000955

申请日：2012-10-12

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： PAULS, Heinz W. ,  LAUFER, Radoslaw ,  LIU, Yong ,  LI, Sze-Wan ,  FORREST, Bryan T. ,  LANG, Yunhui ,  PATEL, Narendra Kumar B. ,  EDWARDS, Louise G. ,  NG, Grace ,  SAMPSON, Peter Brent ,  FEHER, Miklos ,  AWREY, Donald E.

IPC: C07D401/00 ,  A61K31/416 ,  A61P35/00 ,  C07D231/56 ,  C07D401/02 ,  C07D401/14 ,  C07D403/02 ,  C07D405/14 ,  C07D409/14 ,  C07D451/06 ,  C07D491/107

CPC classification number: C07D231/56 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D403/10 ,  C07D405/14 ,  C07D409/12 ,  C07D409/14 ,  C07D413/04 ,  C07D413/10 ,  C07D413/14 ,  C07D451/06 ,  C07D491/107 ,  C07D493/10

Abstract: The present teaching provide indazole compounds represented by Structural Formulae (I) or (I') or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof as protein kinase inhibitors, such as TTK protein kinase, polo-like kinase 4 (PLK4) and Aurora kinases having anticancer activity against breast cancer cells, colon cancer cells, and ovarian cancer cells.

Abstract translation: 本教导提供由结构式（I）或（I'）表示的吲唑化合物或其药学上可接受的盐。 还描述了作为蛋白激酶抑制剂的药物组合物及其使用方法，例如对乳腺癌细胞，结肠癌细胞和卵巢癌细胞具有抗癌活性的TTK蛋白激酶，polo样激酶4（PLK4）和Aurora激酶。

公开(公告)号：WO2009015485A8

公开(公告)日：2009-02-05

申请号：PCT/CA2008/001415

申请日：2008-08-01

Applicant: University Health Network ,  PAULS, Heinz, W. ,  FORREST, Bryan, T. ,  SAMPSON, Peter, Brent ,  LIU, Yong ,  LAUFER, Radoslaw ,  LANG, Yunhui ,  FEHER, Miklos ,  YAO, Yi ,  PAN, Guohua

Inventor： PAULS, Heinz, W. ,  FORREST, Bryan, T. ,  SAMPSON, Peter, Brent ,  LIU, Yong ,  LAUFER, Radoslaw ,  LANG, Yunhui ,  FEHER, Miklos ,  YAO, Yi ,  PAN, Guohua

IPC: C07D211/58 ,  A61K31/17 ,  A61K31/397 ,  A61K31/40 ,  A61K31/445 ,  A61P3/10 ,  A61P35/00 ,  C07C275/32 ,  C07D205/04 ,  C07D207/50 ,  C07D211/56

Abstract: A CPTl inhibitor compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof: or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject having cancer comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.